This textbook summarizes the state of the art in the management of locally advanced and metastatic prostate cancer with the aim of providing the knowledge required for optimal treatment decision making in individual cases. Readers will find comprehensive coverage of the latest developments in surgery, radiotherapy, androgen deprivation therapy (ADT), chemotherapy, and immunotherapy. The role of the hormonal therapies abiraterone and enzalutamide and docetaxel-based chemotherapy in castration-resistant prostate cancer and hormone-sensitive metastatic disease is carefully evaluated. Among the other therapies discussed are LHRH agonists and antagonists, cabazitaxel, radium-223, and various novel agents still under clinical trials. The section on surgical approaches addresses, among other topics, the use of robot-assisted radical prostatectomy, pelvic lymphadenectomy, and the benefits of adjuvant and neoadjuvant therapy. The current role of external beam radiotherapy, alone or in combination with ADT and brachytherapy, for locally advanced disease is reviewed. Management of Advanced Prostate Cancer will be a valuable resource for practitioners at all levels of expertise.

This text provides a comprehensive review of pathophysiology, molecular and cell biology aspects of CRPC, discusses all major clinical trials that have led to approval of 6 new drugs since 2004, explores the role of bone preservation strategies, in depth analysis of combination and sequencing strategies, outlines upcoming novel drugs and trends in research, and stresses the role of palliative care in this incurable disease. Managing Metastatic Prostate Cancer in Your Urological Oncology Practice will serve as a very useful resource for physicians and researchers dealing with, and interested in prostate cancer. It provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and will include the most up to date scientific and clinical information.

Although much progress has been made in the four years since the first edition of Management of Prostate Cancer, prostate cancer remains a significant biological, me- cal, and personal challenge for millions of men. In this interval, some important trends and observations have emerged that represent real progress in the field and which will shape the direction of clinical practice and research in the next 5–10 years. These obs- vations include: (1) a decline in prostate-related cancer mortality in the United States, likely owing to a combination of factors including screening, more aggressive and earlier therapy, and improvements in specific therapies; (2) a significant downward pathological stage migration, so that an individual’s chance of cure for a given stage, grade, and PSA is better now than it was early in the PSA era, even without associated improvements in individual therapies; (3) the recognition of new PSA isoforms that may refine screening strategies; (4) several randomized, phase III clinical trials demonstrating survival adv- tages of one form of therapy over another in selected populations (external beam rad- therapy with adjuvant hormones vs radiotherapy alone, radical prostatectomy vs observation); (5) a focus on the biology of bone and bone metastasis, and new agents that reduce skeletal-related events and which may inhibit the growth of new metastases; (6) second-generation anti-PSMA antibodies with improved potential for imaging and therapy; (7) the development and widespread adoption of nomograms that assist in cli- cal decision-making for individual patients; (8) the identification of new genes that

Carcinoma of the prostate increasingly dominates the attention of urologists for both scientific and clinical reasons. The search for an explanation and the prediction of the variable behaviour of the malignant prostatic cell continues unabated. The search for more precise tumour staging and more effective treatment is equally vigorous. Editors Andrew Bruce and John Trachtenberg have assembled acknowledged leaders in prostate cancer to present those areas of direct interest to the clinician. There are a number of other topics that might have been considered but most of these, such as experimental tumour models or biochemical factors affecting cell growth, still lack immediate application for the clinician. Carcinoma of the prostate continues to have its highest incidence in the western world, and the difference in comparison with the incidence in the Far East appears to be real and not masked by diagnostic or other factors. A number of other epidemiological aspects need careful analysis: Is the incidence increasing? Is the survival improving? Is the prognosis worse in the younger patient? Epidemiological data are easily misused and misinterpreted so that a precise analysis of the known facts makes an important opening chapter to this book.

A Doody's Core Title 2012 Emerging Cancer Therapeutics is a trinary, hard cover, periodical that is designed to provide an up-to-date evidence-based review of a dedicated emerging cancer therapy topic of interest to clinicians and scientists who are involved in the care of patients receiving cancer treatment. It will serve as both a reference and instructional tool for students, housestaff, fellows, practicing clinical oncologists, radiation oncologists, surgical oncologists, cancer biologists, and interdisciplinary colleagues throughout the oncology spectrum. With contributions from experts across the United States and Canada, Prostate Cancer details the current management of prostate cancer and reviews new therapies in development for prostate cancer, with an emphasis on castration-resistant prostate cancer (CRPC). Coverage includes discussion of multiple new agents that have been shown to impact overall survival or improve skeletal-related events in metastatic CRPC as well as articles covering new data on screening and prevention, integration of surgery and radiation with newly emerging medical therapies, and coverage of the newest developments in immunotherapy. This book is a valuable tool for clinicians, nurses, researchers, medical students, residents, and fellows. Included in Prostate Cancer: Updates in Prostate Cancer Prevention Prostate Cancer Screening, 2011 Current Surgical Approaches to Primary Prostate Cancer Treatment Updates in Radiation Therapy for Prostate Cancer: Dose Matters An Update on Androgen-Deprivation Therapy for Advanced Prostate Cancer Novel Androgen Receptor Therapeutic Targets for Advanced Prostate Cancer New Understanding of Metabolic Complications of Androgen-Deprivation Therapy Current State of Docetaxel-Based Therapy in Castration-Resistant Prostate Cancer Second-Line Chemotherapy for Castration-Resistant Prostate Cancer Emerging Role of Immunotherapy in the Treatment of Prostate Cancer Novel Bone-Targeted Therapy in Metastatic Prostate Cancer Emerging Treatment Strategies for Metastatic Prostate Cancer: The Next Step Forward

Do you manage patients with prostate cancer? Could you use an expert guide examining all possible management options? Prostate Cancer: diagnosis and clinical management providesurologists and oncologists of all levels with up-to-date, evidence-based guidance to the diagnosis, treatment and clinical management of a disease which accounts for a quarter of all cancers affecting men. Designed to be as practical and accessible as possible, leading experts discuss key issues in prostate cancer management and examine how to deliver best practice in the clinical care of their patients. Topics covered include: What must be considered when counseling newly-diagnosed cancer patients Radical surgery options for prostate cancer Novel therapies for localized prostate cancer How should metastatic prostate cancer be diagnostic and managed What are the best methods of administering end of life care for the patient Brought to you by a highly experienced editor team, and containing key points, management algorithms, practice tips and the latest AUA and EAU clinical guidelines, this is the ideal consultation tool for doctors both on the wards and in the office.

This book comprehensively covers application of salvage therapy in reccurrent prostate cancer. Chapters focus on specific issues associated with a range of surgical and oncological management techniques and strategies including hormone therapy, lymphnode dissection, robotic prostatectomy and salvage reirradiation after locoregional failure. Learning objectives, and definitions of keywords are provided to aid the reader develop a thorough understanding of the topic and reinforce the key points covered in each chapter. Salvage Therapy for Prostate Cancer provides a detailed practically applicable guide on how salvage therapy can be utilised in the treatment of prostate cancer. It represents a valuable resource for trainee and practicing urologists, oncologists, and specialist nurses.

Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges’ report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.